

**PATENT SPECIFICATION No. (11)**

51821

*Date of Application and Filing Complete  
Specification: (22) 29 Sept 1981  
(21) No. 2257/81*

51821



*Application made in: (33) France (FR)  
(31) No. 8021095 (32) 2 Oct 1980  
(31) No. 8106916 (32) 7 Apr 1981*

*Complete Specification Published:  
(44) 1 April, 1987.*

*(51) Int. Cl. <sup>4</sup>  
C07D 209/42  
A61K 31/405  
© Government of Ireland 1987*

**COMPLETE SPECIFICATION**

(54) **SUBSTITUTED IMINO-DIACIDS, THEIR PREPARATION  
AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM**

**THE BRITISH LIBRARY**

**8 JUN1987**

**SCIENCE REFERENCE AND  
INFORMATION SERVICE**


**PATENT APPLICATION BY (71) ADIR, A FRENCH COMPANY OF 22  
RUE GARNIER, 92200 NEUILLY-SUR-SEINE, FRANCE.**

**Price 90p**

**BEST AVAILABLE COPY**

The present invention relates to new substituted imino-diacids, and in particular to substituted perhydroindole-dicarboxylic acids, their preparation and pharmaceutical compounds containing them.

- 5 The invention relates specifically to the compounds with the general formula:




- 10 wherein:

$\text{R}_1$  represents a lower alkyl group having from 1 to 4 carbon atoms,

$\text{R}_2$  represents a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms,

- 15  $\text{R}_3$  represents a straight or branched alkyl group, a mono- or dicyclo-alkyl group, each of these groups having a maximum of 9 carbon atoms in total, or a substituted alkyl group of the formula:

-3-



in which:

- $\text{R}_4$  = H, a lower alkyl ( $\text{C}_1$  to  $\text{C}_4$ ) or a cycloalkyl  
 5 ( $\text{C}_3$  to  $\text{C}_6$ )  
 $\text{R}_5$  = H, a lower alkyl ( $\text{C}_1$  to  $\text{C}_4$ ), a cycloalkyl  
 ( $\text{C}_3$  to  $\text{C}_6$ ) or an alkoxy carbonyl and  
 $p$  = 1 or 2

The compounds of the invention contain at least one  
 10 carboxy group: two in the case where  $\text{R}_2$  = H; and at  
 least one salt-forming amino group: The invention  
 thus also relates to the salts of the compounds of the  
 formula (I), especially those obtained with a thera-  
 apeutically compatible inorganic or organic base.

15 The invention also relates to the addition salts of the  
 compounds of formula (I), especially those obtained with  
 a therapeutically compatible inorganic or organic acid.

The compounds of formula (I) contain at least 3 asym-  
 metric carbon atoms. Depending on the position of the  
 20 substituents and the degree of hydrogenation, there are  
 from 3 to 6 centres of asymmetry. The racemic

compounds may be divided into their diastereoisomeric or epimeric mixtures, or resolved into their enantiomers in a known manner. The various isomers form part of the invention, as do the racemic compounds.

- 5 The compounds preferred are those corresponding to formula (I) in which  $R_3$  is a straight or branched ( $C_3$  to  $C_8$ )-alkyl group, a ( $C_4$  to  $C_8$ )-cycloalkylalkyl group, or a substituted alkyl group  $-CH_2-S-CH(R_4)R_5$  with  $R_4 = H$  or an alkyl group and  $R_5 =$  an alkoxycarbonyl group, the  
10 alkyl and alkoxy groups having from 1 to 4 carbon atoms. In addition,  $R_1$  may usefully be a methyl radical.

- The compounds according to the invention, and also the salts thereof, have interesting pharmacological properties. In particular, they have an inhibiting  
15 effect on certain enzymes, such as the carboxypolypeptidases, the encephalinases or kininase II. They inhibit particularly the transformation of the decapeptide angiotensin I to the octapeptide angiotensin II, which is responsible for certain cases of arterial  
20 hypertension, by acting upon the converting enzyme.

The therapeutic use of these compounds thus makes it possible to reduce or even eliminate the activity of these enzymes responsible for hypertension or cardiac

-5-

insufficiency. The effect on kininase II results in an increase in the circulating bradykinin and also a reduction in the arterial pressure by this means.

5 The invention also relates to the pharmaceutical compositions which contain as active ingredient at least one compound of the general formula I or one of its physiologically tolerable addition salts with an inorganic or organic base or acid, in conjunction with an inert, non-toxic, pharmaceutically acceptable carrier.

10 For therapeutic use, the compounds of the general formula I or the salts thereof are prepared in the form of pharmaceutical preparations suitable for intravenous or oral administration. In addition to the active ingredient, the pharmaceutical compositions according to  
15 invention contain one or more inert, non-toxic carriers suitable for pharmaceutical use, and/or a binding agent, an aromatising agent, a disintegrating agent, a sweetener, a lubricant or a liquid excipient suitable for intravenous administration.

20 The pharmaceutical compositions according to the invention may also contain another active ingredient having a synergistic or complementary effect.

Among the latter active ingredients which may be


mentioned are a diuretic and, in particular, a  
saliuretic, such as for example a thiazide, a dihydro-  
thiazide, a chlorosulphamide, a dihydrobenzofuran 2-  
carboxylic acid or a derivative of phenoxyacetic acid.  
5 Examples of such compounds are N-(3'-chloro-4'-sulph-  
amoylbenzamido)-2-methylindoline, ethacrynic acid and  
furosemide.

It is also possible to add  $\alpha$ -adrenolytic substances  
such as prazosin or any other anti-hypertensive  
10 substance.

The useful posology may vary widely, depending on the  
age and weight of the patient, the severity of the  
symptoms and the method of administration. Oral admin-  
istration is preferred, but intravenous administration  
15 is also perfectly suitable for the treatment of hyper-  
tension. In general terms, the unit dose will  
preferably range between 5 and 100 mg.


The invention includes a process for the preparation of  
the compounds of general formula I, which process com-  
20 prises subjecting an alkyl ester of perhydroindole di-  
carboxylic acid of the general formula II:

-7-




5 wherein the meaning of the symbol  $\text{R}_1$  remains the same as in formula I,

and  $\text{R}'$  represents a lower alkoxy or hydroxy radical, to a reductive alkylation reaction by means of a compound of the general formula III:



wherein the meaning of the substituents  $\text{R}_2$  and  $\text{R}_3$  remains the same as in formula I, in order to obtain  
15 an amine of the general formula IV:



wherein R' has the meaning given previously for formula II and the symbols R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> retain the meanings provided before.

and after reductive alkylation the intermediate compound  
5 obtained is subjected, if necessary, to the usual de-protection processes, such as for example total or partial saponification and/or hydrogenolysis, and is thus converted into a compound formula (I).

The compounds of the general formula II are described in  
10 or may be synthesised in accordance with the European Patent Application published under No. 0031741. The above-mentioned reductive alkylation uses the process described by R.F. BORCH, M.D. BERNSTEIN, and H. DUPONT DURST, JACS 93, 2897 (1971). The process is  
15 preferably carried out in an alcoholic medium and in the presence of a neutral dehydrating agent and of an organic or inorganic cyanoborohydride.

The following example illustrates the preparation process, but does not result in obtaining a compound  
20 of the invention.

(3S)-2-[N-(1-carboxyethyl)-(S)-alanyl]-3-carboxy-1, 2, 3, 4-tetrahydroisoquinoline.



Step A

Laevorotatory tetrahydroisoquinoline-3-carboxylic acid.

15 g of (S)-8-phenylalanine are introduced into a three-necked flask surmounted by a condenser and then 34 ml of  
5 a 40% solution of formaldehyde, and 105 ml of concentrated hydrochloric acid are added.

The vessel is heated for 30 minutes over a boiling water-bath. A clear solution is thus obtained, the reaction medium is allowed to cool to room temperature, and then  
10 15 ml of formaldehyde and 30 ml of concentrated hydrochloric acid are added thereto. The mixture is then heated for 3 hours under reflux, and afterwards allowed to cool. The precipitate is then separated off by filtration. After drying without heat, it is taken up  
15 in 200 ml of boiling water and 400 ml of hot ethanol. The solutions are combined and neutralised by adding a 10% ammonia solution.

Tetrahydroisoquinoline-3-carboxylic acid crystallises. The crystalline mixture is left to stand overnight in a  
20 refrigerator, and then the precipitate is separated off, centrifuged and washed with ethanol. 17.3 g of crude product are thus obtained. The product is dried under vacuum over phosphoric acid.

Analysis  $C_{10}H_{11}NO_2 = 177$

	C%	H%	N%
Calculated	67.78	6.26	7.90
Found	66.87	6.20	7.96

5 Infra-red spectrum

$NH_2^+$  Band at  $2800 - 2400\text{ cm}^{-1}$   
 $COO^-$  Carbonyl band at  $1630\text{ cm}^{-1}$

Rotatory power

$\alpha_D = -108^0$  ( $c = 2.2$  normal NaOH)

10 Step B

(3S)-methyl 1,2,3,4-tetrahydroisoquinoline-3-carboxylate hydrochloride.

In succession 5 g of tetrahydroisoquinoline 3-carboxylic acid and 30 ml of methanol are introduced into a three-necked flask. 6 g of thionyl chloride are added to this suspension by pouring carefully, taking care that the temperature does not exceed  $0, \pm 5^0$ . The addition takes approximately 10 minutes. After the addition is com-

-11-

pleted, stirring is continued for 2 hours at room temperature, and then the mixture is heated to reflux for 1½ hours. Once the mixture has dissolved completely, heating is discontinued and the mixture is then evaporated to dryness. The residue is taken up three times in methanol and then evaporated to dryness. Finally, 8 g of colourless crystals are obtained and purified by trituration with ether. The crystals are separated off by filtration, centrifuged, washed with ether and dried. 6.4 g of methyl tetrahydroisoquinoline-3-carboxylate hydrochloride are thus obtained.

Analysis  $C_{10}H_{13}NO_2ClH = 227.69$

	C	H	N	Cl%
Calculated	58.03	6.20	6.15	15.57
15 Found	57.79	6.46	6.38	15.67

Infra-red spectrum

Carbonyl band at  $1735\text{ cm}^{-1}$

$NH_2^+$  band at  $2800 - 2400\text{ cm}^{-1}$

Step C

20 (3S)-2-[(S)-tert.butoxycarbonylalanyl]-3-methoxycarbonyl-1,2,3,4-tetrahydroisoquinoline.

6.01 g (0.0264 mol) of the hydrochloride prepared in the previous step are dissolved in 50 ml of water and the solution is rendered alkaline to pH 11 with  $\text{NH}_4\text{OH}$ , and then extracted with 2 x 50 ml of sulphuric ether. The combined ether solutions are dried over calcium sulphate, filtered and evaporated to dryness. The residual amino ester (5.04 g) is dissolved in 30 ml of dimethylformamide and this solution is added to a stirred solution of 5 g (0.0264 mol) of (S)-tert.-butoxycarbonylalanine in 30 ml of dimethylformamide cooled to 0, + 5°C. In succession 3.6 g (0.0264 mol) of 1-hydroxybenztriazole dissolved in 40 ml of dimethylformamide, and then 5.45 g (0.0264 mol) of dicyclohexylcarbodiimide dissolved in 30 ml of chloroform are added to the solution obtained.

15 The reaction mixture is stirred for 18 hours whilst being allowed to return to room temperature. The dicyclohexylurea which is formed is filtered and the filtrate, evaporated to dryness under 0.1 mm Hg, leaves a residue which is redissolved in 50 ml of ethyl acetate and filtered again to separate off a second run of dicyclohexylurea. The filtrate is washed successively with 80 ml of a saturated aqueous solution of NaCl, 2 x 40 ml of a 10% aqueous solution of citric acid, again with 80 ml of a saturated aqueous solution of NaCl, 2 x 40 ml of a saturated aqueous solution of  $\text{NaHCO}_3$ , and finally with a saturated aqueous solution of

-13-

NaCl until neutral.

The organic phase is dried over  $\text{CaSO}_4$ , filtered and evaporated to dryness under vacuum. The evaporation residue is the desired product:

5 Weight : 9.1 g (95%)  
 Melting point : 98-100° (Kofler)

Analysis  $\text{C}_{19}\text{H}_{26}\text{N}_2\text{O}_5$

	C	H	N%
Calculated	62.97	7.23	7.73
10 Found	63.15	7.05	7.97

#### Step D

(3S)-2- [(S)-tert.butoxycarbonylalanyl]-3-carboxy-1,2,3,4-tetrahydroisoquinoline.

1.45 g of (0.004 mol) of the compound prepared in the previous step are dissolved in 20 ml of methanol, and 4.4 ml (0.004 mol) of normal aqueous sodium hydroxide solution are added to the resulting solution.

The solution is left for 20 hours at room temperature.

The methanol is evaporated under vacuum by water jet pump and the residue is taken up in 20 ml of water.

51821

-14-

After extraction of the unsaponified material by means of ethyl acetate, the aqueous phase is acidified with 4.4 ml of normal HCl. The precipitate which forms is extracted with 2 x 20 ml of ethyl acetate which is dried over  $\text{CaSO}_4$ , filtered and evaporated. The residue obtained is the desired product:

Weight : 1.3 g (93%)

Analysis  $\text{C}_{18}\text{H}_{24}\text{N}_2\text{O}_5$

		C	H	N%
10	Calculated	62.05	6.94	8.04
	Found	61.54	6.93	7.78

Step E

(3S)-2-[(S)-alany]-3-carboxy-1,2,3,4-tetrahydroisoquinoline.

15 1.1 g (0.00316 mol) of the derivative prepared in the previous step are stirred at + 5°C with 4.5 ml of trifluoroacetic acid whilst protected from humidity.

The resulting solution is concentrated to dryness under 0.1 mm Hg. The crystalline, hygroscopic evaporation residue is the desired product, in the form of the trifluoroacetate solvated by means of 0.5 mol of tri-

20

-15-

fluoroacetic acid:

Weight : 1.3 g (98%)

Analysis  $C_{32}H_{35}F_9N_4O_{12}$ 

	C%	H%	N%
5    Calculated	45.83	4.21	6.68
Found	45.99	4.62	6.55

0.7 g (0.0019 mol) of the above trifluoroacetate are transformed into 0.45 g (94%) of the corresponding free amino acid by being passed over 50 g of sulphonated  
 10 resin (Dowex 50 W x 8  $H^+$ ), followed by washing out with 500 ml of normal ammonia solution.

Melting point : 170°C (decomposition).

Step F

(3 $\underline{S}$ )-2-[( $\underline{S}$ )-N-(1-carboxyethyl)-alanyl]-3-carboxy-1,2,3,  
 15 4-tetrahydroisoquinoline.

0.849 g (0.0034 mol) of 2-[( $\underline{S}$ )-alanyl]-3-carboxy-1,2,3, 4-tetrahydroisoquinoline are dissolved in the presence of 1.9 g (0.0216 mol) of pyruvic acid at 25°C in 22 ml of normal sodium hydroxide solution and 50ml of pH 7  
 20 buffer taken from a solution prepared from 50 ml of 0.1

molar solution of monosodium phosphate and 29.1 ml of N/10 sodium hydroxide solution. 0.45 g (0.0072 mol) of sodium cyanoborohydride are added all at once. The reaction mixture is left at room temperature for 22 hours.

The excess sodium cyanoborohydride is decomposed by the addition of 6 ml of concentrated hydrochloric acid. The resulting solution is passed over an ion exchange resin (Dowex 50  $H^+$ ). After washing out the resin with distilled water until there are no chlorine ions present, the product fixed on the resin is removed by washing out with 1 litre of normal aqueous ammonia solution. The ammoniacal solution is concentrated to dryness under vacuum by water jet pump. The evaporation residue is the monoammonium salt of the desired product. Weight obtained: 0.8 g (69.7%)

Analysis  $C_{16}H_{23}N_3O_5$

	C%	H%	N%
Calculated	56.96	6.64	12.95
20 Found	57.79	6.69	12.70

The following Examples illustrate the invention.

EXAMPLE 1

1-{(S)-N-[(1RS)-1-carboxyethyl]-alanyl}-2-carboxyperhydroindole.



-17-

Step A

(2RS)-2-carboxyindoline.

31.5 g of the above indoline (86%) are obtained by saponification in 250 ml of normal sodium hydroxide solution and 150 ml of ethanol for 18 hours at room temperature of 43 g (0.224 mol) of the corresponding ethyl ester prepared according to E.J. COREY et al. (J. Amer. Chem. Soc. 1970 92, p. 2476).

The aqueous alcoholic solution is concentrated to  $\frac{1}{2}$ , neutralised with 25 ml of 10N hydrochloric acid, and the precipitate formed is filtered, washed with water, and dried.

The crude acid is purified by being passed through an ion exchange resin column (Dowex 50 W x 8 H<sup>+</sup>) and washed out with 2N aqueous ammonia solution. The ammonium salt obtained is dissolved in the minimum quantity of water and the acid precipitated by the theoretical amount of HCl. It is centrifuged, washed with water, and air-dried.

Analysis (of ammonium salt)  $C_9H_{12}N_2O_2$ 

	C%	H%	N%
Calculated	59.99	6.71	15.54
Found	60.22	6.71	15.06
5	59.93	6.71	15.29

Step 8

(2S)-2-carboxyindoline.

60.5 g (0.37 mol) of (DL)-2-carboxyindoline prepared in Step A are added to a solution of 44.9 g (0.37 mol) of (+)- $\alpha$ -methylbenzylamine in 400 ml of anhydrous ethanol. The precipitate obtained is centrifuged and digested in 350 ml of anhydrous isopropanol under reflux. After cooling, the suspension is filtered, and the precipitate is washed with a little isopropanol and dried.

15 Weight of (L)-2-carboxyindoline, (+)- $\alpha$ -methylbenzylamine salt obtained 29.8 g.

$$\alpha_D^{21} = 5.3^\circ \text{ (C = 1\% ethanol)}.$$

The (2S)-2-carboxyindoline is prepared in a theoretical yield by dissolving 10 g of the above-mentioned salt

-19-

(0.029 mol) in 50 ml of water and acidifying it with 29 ml of normal hydrochloric acid.

The precipitate is centrifuged, washed with water, distilled, and dried. Optical purity : 96% (VPC after  
5 converting into the form of (-)-camphanic acid amide.

The (2R)-2-carboxyindoline was obtained by the same process, starting from (RS)-carboxyindoline and (-)- $\alpha$ -methylbenzylamine.

The absolute configurations of the (S) and (R) acids were  
10 determined as follows:

Analytical amounts (approx. 0.5 g) of each of the acids are converted into ethyl esters by treatment with thionyl chloride and ethanol according to the process described in Step C.

15 The esters are reduced by lithium aluminium hydride according to E.J. COREY (loc.cit.) to the corresponding primary alcohols, which are identified by their rotatory power with the alcohols described by E.J. COREY, the respective absolute configurations of which are known.

Step C

(2S)-2-ethoxycarbonylperhydroindole.

11 g of (L)-2-carboxyindoline, (+)- $\alpha$ -methylbenzylamine  
salt (0.032 mol) prepared in Step B are dissolved in 100  
5 ml of water and converted into the corresponding acid by  
the addition of 32 ml of N HCl. The acid is centrifuged,  
washed with water and dried in a desiccator over phos-  
phoric anhydride, then suspended in 50 ml of anhydrous  
ethanol. At a temperature of 0, +5°, 3.9 ml of thionyl  
10 chloride are added within 10 minutes whilst stirring,  
and stirring is continued for 1 hour at 25°C, then 1  
hour at 50°C.

The mixture is left overnight at 25°, then concentrated  
to dryness under vacuum by water jet pump at 40° and  
15 taken up with 50 ml of anhydrous benzene and  
centrifuged.

The (2S)-2-ethoxycarbonylindoline hydrochloride obtained  
is hydrogenated in solution in 150 ml of water in the  
presence of 2 g of palladinised charcoal for 8 hours at  
20 45°C under 50 kg/cm<sup>2</sup> pressure.

After cooling and filtration of the catalyst, the fil-  
trate is evaporated to dryness. The residue is the

-22-

After 65 hours' stirring at 25°, the dicyclohexylurea formed is filtered and washed with ethyl acetate. The combined filtrates are washed successively with 80 ml of a saturated aqueous solution of NaCl, 2 x 40 ml of concentrated citric acid solution, 2 x 40 ml of a saturated aqueous solution of NaHCO<sub>3</sub>, then again with 2 x 40 ml of NaCl solution.

The organic solution is dried over CaSO<sub>4</sub>, filtered, concentrated to dryness under vacuum by water jet pump, and the residue is taken up in 100 ml of ethyl acetate. The solution is filtered to eliminate the last traces of dicyclohexylurea, and the filtrate which is concentrated to dryness leaves a residue which is the desired product in the form of a very viscous oil.

Weight : 3.8 g (81%)

Analysis C<sub>19</sub>H<sub>32</sub>N<sub>2</sub>O<sub>5</sub>

	C%	H%	N%
Calculated	61.93	8.75	7.60
Found	61.76	8.56	7.77

## 20 Step E

(2S)-N-[(S)-t-Boc-alanyl]-2-carboxyperhydroindole.

3.6 g (0.0098 mol) of ester obtained in Step D are dissolved in 30 ml of methanol in the presence of 11 ml of

-23-

normal aqueous sodium hydroxide solution.

After 20 hours at 25°, the methanol is evaporated under vacuum by water jet pump and 60 ml of water are added. The solution is washed with 2 x 50 ml of ethyl acetate to eliminate the unsaponified material, then acidified with 17 ml of N hydrochloric acid. The white precipitate formed is extracted with 2 x 50 ml of ethyl acetate, which are combined and washed with water, dried over CaSO<sub>4</sub>, filtered and concentrated to dryness. The residue is the desired product:

Weight : 1.9 g (57%)

Analysis C<sub>17</sub>H<sub>28</sub>N<sub>2</sub>O<sub>5</sub>

	C%	H%	N%
Calculated	59.98	8.29	8.23
15 Found	59.10	8.16	7.81

#### Step F

(2S)-1-[(S)-alanyl]-2-carboxyperhydroindole.

1.6 g (0.0047 mol) of acid prepared in the previous step (e) are stirred at a temperature of 0, + 5°C in solution in 10 ml of trifluoroacetic acid for 1 hour, and then for another 15 minutes at room temperature.

After being evaporated to dryness under vacuum by vane

-24-

pump, the residue dissolved in 15 ml of water is passed over an ion exchange resin column (Dowex W +  $8H^+$ ).

The column is washed out with 1 litre of 2 N aqueous ammonia solution. The washings are concentrated to dryness under vacuum. The residue obtained is the desired product.

Weight : 0.90 g (95%)

Analysis  $C_{12}H_{20}N_2O_3$

	C%	H%	N%
10 Calculated	59.98	8.39	11.10
Found	58.53	8.24	11.43

#### Step G

(2S)-1-{(S)-N-[(1R)-1-carboxyethyl]-alanyl}-2-carboxy-perhydroindole.

- 15 0.7 g (0.00291 mol) of (2S)-N-[(S)-alanyl]-2-carboxy-perhydroindole prepared in the previous step (F) and 1.67 g (0.0183 mol) of pyruvic acid are dissolved in 18 ml of normal aqueous sodium hydroxide solution and 40 ml of pH 7 buffer, and the solution obtained is sub-
- 20 jected to reduction with 0.400 g (0.0064 mol) of sodium cyanoborohydride as described in Example 1, Step F.

After treatment with concentrated hydrochloric acid and being passed over an ion exchange resin (Dowex 50  $H^+$ ), the final ammoniacal washings, when evaporated to dryness,

-25-

leave 0.76 g (79%) of residue which is the desired product in the form of monoammonium salt.

Analysis  $C_{15}H_{27}N_3O_5$

	C%	H%	N%
5    Calculated	54.70	8.26	12.76
Found	54.10	7.78	12.77

EXAMPLE 2

(2S)-1-{N-[2-((1R,5S)-1-ethoxycarbonylthio)-(1R,5S)-1-ethoxycarbonylthio]-(S)-alanyl]}-2-carboxyperhydroindole.

- 10 1 g (4.17 m mols) of (2S)-1-[(S)-alanyl]-2-carboxy-perhydroindole, prepared as described in Example 1, Step F, and 4.72 g (19 m mols) of ethyl [(1R,5S)-1-ethoxycarbonylthio]-pyruvate are dissolved in 50 ml of anhydrous ethanol in the presence of 15 g of molecular
- 15 sieve 4 Å. After 45 minutes' stirring at room temperature, 0.25 g of sodium cyanoborohydride in solution in 2.25 ml of anhydrous ethanol are added within 6 hours.

- After the molecular sieve has been separated off by filtration, the filtrate is concentrated to dryness under
- 20 reduced pressure and the residue is dissolved in 100 ml of sulphuric ether. The solution is extracted with 2 x 100 ml of distilled water, then dried over calcium sulphate, filtered and chromatographed over 200 g of silica (Merck F 254), washing out with a 180/20 methylene chloride/



-26-

methanol mixture. 0.5 g (25%) of the desired product are obtained in the form of the sodium salt.

Analysis  $C_{22}H_{35}N_2Na O_7S$

	C%	H%	N%	S%
5    Calculated	53.43	7.13	5.66	6.48
Found	53.28	7.09	5.19	5.92

The intermediate ethyl [(1*RS*)-1-ethoxycarbonyl-ethylthio]-pyruvate is prepared by condensing ethyl bromo-pyruvate with (1*RS*)-ethyl thiolactate in the presence of  
 10 pyridine according to the process described for related derivatives in the J. of Heter. Chem. (1973) 10/4 p. 679-681).

b.p.<sub>15</sub> = 165-170

Yield 67%

### 15    EXAMPLE 3

(2*S*)-1-[N-(2-ethoxycarbonylmethylthio-(1*RS*)-1-ethoxycarbonyl-ethyl)-(1*S*)-alanyl]-2-carboxyperhydroindole.

Prepared as in Example 2, starting from 1 g (4.17 m mols) of (2*S*)-1-[N-(1*S*)-alanyl]-2-carboxyperhydroindole, 4.45 g  
 20 (1.9 mols) of ethyl ethoxycarbonylmethylthiopyruvate and 0.25 g of sodium cyanoborohydride.

-27-

After purification by chromatography, 0.26 g (14%)  
of the desired product are obtained.

Analysis  $C_{21}H_{34}N_2O_7S$

		C%	H%	N%	S%
5	Calculated	55.00	7.47	6.11	6.99
	Found	54.71	7.32	5.94	7.01

The intermediate ethyl ethoxycarbonylmethylthiopyruvate  
is prepared by condensing ethyl bromopyruvate with ethyl  
thioglycolate according to the process described by the  
10 reference quoted in Example 2.

b.p.<sub>15</sub> = 165 -175      Yield 50%

The compounds prepared in the preceding Examples, and also  
other compounds of formula (I) prepared in a similar manner,  
have been collated in the Table which follows. For the sake  
15 of convenience, the symbols A and  $\bar{n}$  are only mentioned for  
the values where A = a benzene ring and  $\bar{n}$  = 1. For all the  
other compounds A means a saturated ring and  $\bar{n}$  = 0 (perhydro-  
indole of formula I').

The Table gives the characteristic values of the compounds  
20 with regard to infra-red (IR) and nuclear magnetic  
resonance (NMR) :

$\underline{s}$  is for singlet,

$\underline{d}$  is for doublet,

$\underline{q}$  is for quadruplet,

25  $\underline{m}$  is for multiplet.

TABLE

Compound No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	FORM (salt)
1 (Ex. 1)	CH <sub>3</sub>	H	CH <sub>3</sub>	ammonium salt
2	CH <sub>3</sub>	C <sub>2</sub> H <sub>5</sub>	-CH <sub>2</sub> -S-CH (cyclopropyl) <sub>2</sub>	—
3	CH <sub>3</sub>	C <sub>2</sub> H <sub>5</sub>	-CH <sub>2</sub> -CH <sub>2</sub> -CH (cyclopropyl) <sub>2</sub>	acid maleate
4	CH <sub>3</sub>	C <sub>2</sub> H <sub>5</sub>	CH <sub>3</sub>	acid maleate
5	CH <sub>3</sub>	C <sub>2</sub> H <sub>5</sub>	-CH <sub>2</sub> -S-CH (cyclohexyl) <sub>2</sub>	sodium salt
6	CH <sub>3</sub>	C <sub>2</sub> H <sub>5</sub>	-CH <sub>2</sub> -S-CH (RS)-CH(CH <sub>3</sub> )-COOC <sub>2</sub> H <sub>5</sub>	sodium salt
7	CH <sub>3</sub>	C <sub>2</sub> H <sub>5</sub>	-CH <sub>2</sub> -S-CH (S)-CH(CH <sub>3</sub> )-COOC <sub>2</sub> H <sub>5</sub>	acid maleate
8	CH <sub>3</sub>	C <sub>2</sub> H <sub>5</sub>	-CH <sub>2</sub> -CH(CH <sub>3</sub> ) <sub>2</sub>	sodium salt

TABLE (cont'd 1)


Compound No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	FORM (salt)
9 14 (Ex. 3)	CH <sub>3</sub>	C <sub>2</sub> H <sub>5</sub>	-CH <sub>2</sub> -S-CH <sub>2</sub> -COOC <sub>2</sub> H <sub>5</sub>	—
10	CH <sub>3</sub>	C <sub>2</sub> H <sub>5</sub>	n-C <sub>4</sub> H <sub>9</sub>	sodium salt
11	CH <sub>3</sub>	C <sub>2</sub> H <sub>5</sub>	n-C <sub>3</sub> H <sub>7</sub>	—
12	CH <sub>3</sub>	C <sub>2</sub> H <sub>5</sub>	-CH <sub>2</sub> - 	sodium salt
13	CH <sub>3</sub>	C <sub>2</sub> H <sub>5</sub>	i-C <sub>3</sub> H <sub>7</sub>	sodium salt
14	CH <sub>3</sub>	C <sub>2</sub> H <sub>5</sub>	C <sub>2</sub> H <sub>5</sub>	sodium salt
15	CH <sub>3</sub>	C <sub>2</sub> H <sub>5</sub>	n-C <sub>5</sub> H <sub>11</sub>	sodium salt
16	CH <sub>3</sub>	C <sub>2</sub> H <sub>5</sub>	n-C <sub>6</sub> H <sub>13</sub>	—
17	CH <sub>3</sub>	C <sub>2</sub> H <sub>5</sub>	n-C <sub>8</sub> H <sub>17</sub>	trifluoroacetate.

TABLE (cont'd 2)

Comp.	I.R. ( $\nu_s$ in $\text{cm}^{-1}$ )	NMR in $\text{CDCl}_3$ : chemical shifts (ppm)/TMS
1	NH : 3500-2500 C=O : 1600	m. : 3H(4.8-4) Peaks : 18H(2.5-1.3) Peaks :
2		Peaks : 17H(1.6-0.8) 6H(4.5-3.5) 2H(5.7-5.2) 10H(0.7-0.1) 3H(3.2-1.9) 2H(6.35)
3		Peaks : 21H(2.7-1) 6H(4.6-3.7) 11H(0.8-0.1) 4H(11.2) s. : 2H(6.4)
4		Peaks : 20H(2.7-1.1) 4H(10.3) 6H(4.7-3.9) s. : 2H(6.4)
5	NH 3700-3200 CO ester 1730 CO amide 1650-	Peaks : 8H(4.7-3.2) d. : 2H(2.9) 39H(2.5-1)
6	NH 3300 CO ester 1725 CO amide 1620	Peaks : 11H(4.5-2.6) s. : 2H(6.5) 4H exchangeable (11.1) 23H(2.5-1)
7		Peaks : 9H(4.7-3.2) 25H(2.5-1)
8	NH 3600-2300 CO ester 1725 CO amide 1630	Peaks : 6H(3-4.5) d. : 6H(1) 20H(1.2-2.5)

TABLE (cont'd 3)

Comp.	I.R. ( $\nu_s$ in $\text{cm}^{-1}$ )	NMR in $\text{CDCl}_3$ : chemical shifts	(ppm)/TMS
9	NH 3700-2500 C=O ester 1720 C=O amide 1625	Peaks : 18H(2-1) 2H(2.5-2) q. : 4H(4.25) 4H(4.5-3.2) d. : 2H(3) 2H	s. : 2H (3.4) exchangeable
10	NH 3600-3100 C=O ester 1725 C=O amide 1620	Peaks : 6H(3-4.5) 27H(0.1-2.5)	
11	NH 3300 C=O ester 1725 C=O amide 1620	Peaks : 24H(2.4-0.7) s. 2H(6.8) 6H(4.6-3.4)	
12	NH 3300 C=O ester 1725 C=O amide 1610	Peaks : 25H(2.5-0) 6H(4.5-3)	
13	NH 3300 C=O ester 1725 C=O amide	Peaks : 5H(4.5-3) 25H(0.7-2.5) 1H(2.9)	
14	NH 3600-2500 C=O ester 1730 C=O amide 1610	Peaks : 6H(3-4.6) 23H(0.6-2.5)	
15	NH 3300 C=O ester 1725 C=O amide 1610	Peaks : 7H(3-5) 28H(0.5-2.6)	
16	NH <sub>2</sub> <sup>+</sup> 3600-2400 C=O ester 1730 C=O amide 1650-1550	Peaks : 6H(3-4.7) 2H exchangeable (5.9) 30H(0.8-2.6)	
17	NH <sub>2</sub> <sup>+</sup> 3500-2300 C=O ester 1740 C=O amide 1650	Peaks : 6H(3.5-4.6) 3H exchangeable (8-9) 34H(0.5-2.7)	

-31-

61821

Pharmacological study of the compounds of the invention.

The compounds according to the invention were tested by i.v. or p.o. administration to dogs during consciousness.

5 The blood pressure of the dogs was measured by means of a pressure detector (Statham P 23 Db) after catheterisation of the aorta through the femoral artery. The findings were recorded by means of a recording apparatus (Brush 400).

10 Angiotensin I and angiotensin II were injected into the animals intravenously at a dosage of 0.3  $\mu$ /kg. The compounds according to the invention were then administered orally or intravenously at a dosage of from 1 to 5 mg/kg.

15 It was observed that there was inhibition of the hypertensive effect of angiotensin I ranging from 50 to 100% which occurred 30 to 90 minutes after administration and which remained at from 40 to 80% more than 6 hours after administration. Certain compounds remained active after 24 hours, which is not the case with any compound known hitherto (particularly captopril, which is the only commercially available compound). In addition, the compounds  
20 of the invention seem to have no toxic effect ( $LD_{50} > 500$  mg/kg i.p. in mice).

EXAMPLE OF FORMULATION


	(2S)-1-N-[2-((1S)-1-ethoxycarbonylethylthio)-(1R)-1-ethoxycarbonylethyl]-(S)-alanyl}-2-carboxyperhydroindole (maleate).....	10 mg
5	wheat starch.....	120 mg
	cornstarch .....	115 mg
	casein treated with formaldehyde.....	20 mg
	magnesium stearate.....	15 mg
	talC.....	20 mg

10    for 1 tablet




CLAIMS

1. Compounds corresponding to the general formula:



in which

- 5  $R_1$  represents a lower alkyl group having from 1 to 4 carbon atoms,
- $R_2$  represents a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms,
- 10  $R_3$  represents a linear or branched alkyl group, or a mono- or di-cycloalkyl-alkyl group, each of these groups having a maximum of 9 carbon atoms in total, or a substituted alkyl group of the formula:




in which

- 15  $R_4 = H, (C_1-C_4)$ -lower alkyl or  $(C_3-C_6)$ -cycloalkyl,

$R_5 = H, (C_1-C_4)$ -lower alkyl,  $(C_3-C_6)$ -cycloalkyl or alkoxy-carbonyl, and

$p = 1$  or  $2$ , in their racemic form or in the form of their optical isomers, and their salts obtained with a therapeutically compatible mineral or organic base, or their addition salts obtained with a pharmaceutically compatible mineral or organic acid.

2. Compounds according to claim 1, corresponding to formula (1), in which  $R_3$  is a linear or branched  $(C_3-C_8)$ -alkyl group, a  $(C_4-C_8)$ -cycloalkylalkyl or a substituted alkyl of the formula:



in which  $R_4 = H$  or  $(C_1-C_4)$ -alkyl and  $R_5 = ((C_1-C_4)$ -alkoxy)-carbonyl.

3. Compounds according to claim 2, corresponding to the formula (1) in which  $R_1$  is a methyl radical.

4. 1-(N-[2-(1-(RS)-ethoxycarbonylethylthio)-1-(RS)-ethoxycarbonylethyl]-(S)-alanyl)-2-(S)-carboxy-perhydroindole, its (S)-isomers and their maleate.


5. 1-(N-[1-(R,S)-ethoxycarbonyl-3-methylbutyl]-(S)-alanyl)-2-(S)-carboxy-perhydroindole, its (S)-isomer and their sodium salt.

6. 1-(N-[1-(R,S)-ethoxycarbonylpentyl]-(S)-alanyl)-2-(S)-carboxy-perhydroindole, its (S)-isomer and their sodium salt.

7. 1-(N-[1-(R,S)-ethoxycarbonylbutyl]-(S)-alanyl)-2-(S)-carboxy-perhydroindole, its (S)-isomer and their sodium salt.

8. 1-(N-[1-(R,S)-ethoxycarbonyl-2-cyclopropylethyl]-(S)-alanyl)-2-(S)-carboxy-perhydroindole, its (S)-isomer and their sodium salt.

9. Process for the preparation of the compounds according to claim 1, characterised in that a dicarboxylic acid alkyl ester of the general formula II:




(II)

in which  $R_1$  has the same meaning as in formula 1, and  $R'$  represents a hydroxy radical or a lower alkoxy radical, is subjected to a reductive alkylation reaction

with a compound of the general formula III:



in which the definition of the substituents  $\text{R}_2$  and  $\text{R}_3$  is the same as in claim 1, to obtain an amine of the general  
5 formula IV:



in which  $\text{R}'$  has the meaning given above for formula II and the symbols  $\text{R}_1$ ,  $\text{R}_2$  and  $\text{R}_3$  retain the meanings given previously, and, after reductive alkylation, this inter-  
10 mediate compound obtained is optionally subjected to customary deprotection processes, such as, for example, total or partial hydrolysis and/or hydrogenolysis, and is thus converted into a compound of the formula (I).

10. Pharmaceutical composition containing as active  
15 ingredient at least one compound according to any one of claims 1 to 8, in conjunction with an excipient or a therapeutically compatible non-toxic inert carrier.

11. Compounds substantially as hereinbefore described with reference to the Examples.

12. A process substantially as hereinbefore described with reference to the Examples.

5 13. A pharmaceutical composition substantially as hereinbefore described with reference to the Examples.

Dated this 29th day of September 1981

CRUICKSHANK & CO.

Agents for the Applicants,

Youghal House,

13 Trinity Street,

Dublin 2.



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**